Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$983.8M
40M shares
52-week range
$18.80 – $27.66
60% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
1.3
EV / FCF (TTM)
6.6
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
www.pacira.comNo one on the platform currently holds PCRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,825,501 | $41.3M |
No one on the platform has traded PCRX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 1.4% | — | — | — | ||
| Rev. Growth % | 3.6% | 11.1% | ||||
| Profit Margin % | 1.0% | 0.6% | 0.6% | |||
| Free Cash Flow Margin % | 18.8% | 19.4% | 13.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +2.5% on the P/E track.
At today's price, your expected annual return is +7.8% on the P/E track.
At today's price, your expected annual return is +13.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $754M | +3.3% | $2.89 | $2.82–$2.95 | 8.3× | 4 |
| 2027 | $789M | +4.6% | $3.44 | $3.18–$3.68 | 7.0× | 4 |
| 2028 | $883M | +12.0% | $4.54 | $2.37–$6.71 | 5.3× | 2 |
| 2029 | $866M | -1.9% | $4.38 | $4.21–$4.73 | 5.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.65 | $0.73 | +13.0% |
| 2026-04-30 | $0.61 | $0.60 | -1.6% |
| 2026-02-26 | $0.85 | $0.57 | -32.9% |
| 2025-11-06 | $0.65 | $0.70 | +7.7% |
| 2025-08-05 | $0.72 | $0.74 | +2.8% |
| 2025-05-08 | $0.57 | $0.62 | +8.8% |
| 2025-02-27 | $0.78 | $0.91 | +16.7% |
| 2024-11-06 | $0.72 |
| $0.79 |
| +9.7% |
| $2.1B |
| — |
| MNMDMind Medicine (MindMed) Inc. | $20.69 | +0.44% | $1.6B | — |
| OCSOculis Holding AG | $10.07 | -5.00% | $576M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ENSC One of the longstanding challenges in severe pain management is balancing the therapeutic role of opioids with the risks of misuse and overdose. Our TAAP™ and MPAR® platforms approach that challenge through a chemical redesign; technologies engineered to introduce safety mechanisms into opioid-based treatment. This was one of the central themes we revisited at PAINWeek, where Dr. Lynn Kirkpatrick highlighted the potential impact of this approach: “We now have leading edge abuse and OD protected opioids which could transform care once approved.” $SCLX $PCRX
View on StockTwits ↗
$PCRX Can't remember why I bought this trash, it never goes anywhere
View on StockTwits ↗
$PCRX getting hammered again what a surprise. This stock loves to take a beating. Thank you, sir, may I have another?!?
View on StockTwits ↗
$PCRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.12 up 209.09% YoY • Reported revenue of $192.4M up 6.24% YoY • Pacira BioSciences updated full-year 2026 guidance to total revenue of $735 million to $760 million, non-GAAP SG&A expense of $310 million to $330 million, and stock-based compensation of $54 million to $59 million.
View on StockTwits ↗
$PCRX Progressing along very well. Not many followers here either. Long
View on StockTwits ↗$PCRX reddest day in a while and we are green - how backwards is this stock?
View on StockTwits ↗$PCRX greenest day of the year and this is Red…fitting and expected
View on StockTwits ↗
$PCRX Share Price: $23.10 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $2.76 – $3.41 Target Zone: $4.46 – $5.46 Potential Upside: 53% ROI Time to Expiration: 189 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$PCRX for a year this has been the PERFECT channel trade. Buy at $21 sell at $26 over and over and over. Money.
View on StockTwits ↗
$PCRX reported 0.60 EPS and 177.38 revenue for Q1. http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_content=PCRX&utm
View on StockTwits ↗$PCRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 down -30.00% YoY • Reported revenue of $177.38M up 5.00% YoY
View on StockTwits ↗
What Happens During Surgery May Reduce Opioid Use for Months: https://jlsfund.substack.com/p/what-happens-during-surgery-may-reduce $PCRX
View on StockTwits ↗$PCRX Dam, going down w/health care. Low basis so not near my stop...yet.
View on StockTwits ↗Wall St is expecting 0.55 EPS for $PCRX Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/pcrx?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.